China Mobile Ltd
Change company Symbol lookup
Select an option...
CHL China Mobile Ltd
PRTAX T. Rowe Price Tax-Free Income Fund
AEMD Aethlon Medical Inc
HRVSF Harvest Health & Recreation Inc
UA Under Armour Inc
TRWH Twin River Worldwide Holdings Inc
F Ford Motor Co
JKHY Jack Henry & Associates Inc
JNJ Johnson & Johnson
HMN Horace Mann Educators Corp
Go

Communication Services : Wireless Telecommunication Services | Large Cap Value
Based in China
Company profile

China Mobile Limited is an investment holding company principally engaged in telecommunication and related businesses. Its main businesses include Mobile businesses, Wireline Broadband businesses and Internet of Things (IoT) businesses. Mobile businesses include two categories of services. Voice services include local calls, domestic and international long distance calls, roaming services and voice value-added services. Data services include short message services and multimedia message services, wireless data traffic services and application and information services, such as Mobile Music, Mobile Reading and Mobile Video, among others. Wireline Broadband businesses include the provision of wireline broadband and related services. The Company also provides customer services, including phone bill enquiry, among others. The Company mainly operates businesses in Mainland China.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Postmarket

Last Trade
Delayed
$0.00
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$32.51
Day's Change
-0.69 (-2.08%)
Bid
--
Ask
--
B/A Size
--
Day's High
33.14
Day's Low
32.51
Volume
(Heavy Day)
Volume:
1,631,553

10-day average volume:
1,047,701
1,631,553

NIH to test Lilly's experimental monoclonal antibody treatment in mild and moderate COVID-19 cases

7:58 am ET August 5, 2020 (MarketWatch)
Print

Shares of Eli Lilly & Co. (LLY) gained 0.6% in premarket trading on Wednesday, the day after the National Institutes of Health said it plans to study whether several experimental monoclonal antibodies can treat hospitalized COVID-19 patients. The first therapy to be studied in the Phase 3 randomized, controlled trial is Lilly's LY-CoV555, an antibody that was first detected in a blood sample from a recovered COVID-19 patient. Researchers will evaluate whether the therapy is efficacious in 300 people who have mild or moderate symptoms of COVID-19. Lilly is developing the therapy in partnership with the privately held Abcellera Biologics. Patients in the trial will be given LY-CoV555 or placebo, and all patients will receive the standard of care, which includes Gilead Sciences Inc.'s (GILD) remdesivir. The Food and Drug Administration granted remdesivir an emergency use authorization in May as a treatment for COVID-19 patients. Lilly announced (http://www.marketwatch.com/story/lillys-stock-rises-as-it-announces-late-stage-trial-for-covid-19-drug-in-nursing-homes-2020-08-03) earlier this week that is testing the investigational antibody treatment in a trial to see if it can prevent COVID-19 infections in residents and workers in nursing homes. Lilly's stock is up 17.8% so far this year, while the S&P 500 has rallied 2.3%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

August 05, 2020 07:58 ET (11:58 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.